An In-depth Look At Key Aspects For Small Business Funding

(Pacific Time) at the Parc 55 in San Francisco, California. The presentation may be accessed on January 11, 2017 through the Investor Relations’ Events and Presentations section on Intellipharmaceutics’ website at www.intellipharmaceutics.com . About Intellipharmaceutics Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The Companys patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the efficient development of a wide range of existing and new pharmaceuticals. Based on this technology platform, Intellipharmaceutics has developed several drug delivery systems and a pipeline of products (some of which have received United States Food and Drug Administration (FDA) approval) and product candidates in various stages of development, including Abbreviated New Drug Applications (ANDAs) filed with the FDA (and one Abbreviated New Drug Submission filed with Health Canada) in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract, diabetes and pain. Intellipharmaceutics also has New Drug Application (NDA) 505(b)(2) specialty drug product candidates in its development pipeline. These include Rexista (abuse deterrent oxycodone hydrochloride extended release tablets), based on its proprietary nPODDDS novel Point Of Divergence Drug Delivery System (for which an NDA has been filed with the FDA), and Regabatin XR (pregabalin extended-release capsules). Our current development effort is increasingly directed towards improved difficult-to-develop controlled-release drugs which follow an NDA 505(b)(2) regulatory pathway. The Company has increased its research and development emphasis towards new product development, facilitated by the 505(b)(2) regulatory pathway, by advancing the product development program for both Rexista and Regabatin. The 505(b)(2) pathway (which relies in part upon the approving agencys findings for a previously approved drug) both accelerates development timelines and reduces costs in comparison to NDAs for new chemical entities. An advantage of our strategy for development of NDA 505(b)(2) drugs is that our product candidates can, if approved for sale by the FDA, potentially enjoy an exclusivity period which may provide for greater commercial opportunity relative to the generic ANDA route.

http://finance.yahoo.com/news/intellipharmaceutics-present-biotech-showcase-130000598.html

Conduit CBS and secondary market financing for commercial real estate and multifamily properties with certainty or rate, cost and execution. While micro lending does tend to have a higher rate of interest than traditional loans, you may find that the freedom and flexibility that they can provide will be more than enough of a reason to consider them as being your best bet for the financing your company needs. This commercial mortgage portal allows you to apply to 750 commercial real estate lenders in just four minutes. Consider buying if you believe the real estate in question may grow in value. If you are in the Market looking for a commercial loan we can get you approved for any amount. No social security number required. Once all items are sent, the loan is closed and you receive the funds. We do all types of loans of commercial loans.

In any case, take the time to conduct due diligence and investigate all your options before making any real estate decision. When a company needs to pay for something, it can pay with cash, or it may finance the purchase. Financing means that it gets the money from other businesses or sources, in return for obligations. … Get started to small business financing email These are just some of the issues to consider. This gives you a better ability to forecast your cash flow over time. Find the Perfect Small Business Loan Cash lending, Small Business funding, Receivables factoring, Equipment leasing, Real Estate financing and more…